Rana Therapeutics, a developer of gene-activation therapeutics, has inked a deal to use Santaris Pharma’s locked nucleic acid technology to develop drugs against up to 10 proprietary targets.
In exchange, Santaris will receive an upfront payment, as well as target nomination payments, development milestones, and royalties.
Specific terms of the deal were not disclosed.